Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

DARK SECRETS: Eli lilly ends bimagrumab obesity study weeks after launch | Vintage Vibes

Prague,,Czechia,-,30.,May,2025:,Eli,Lilly,Logo,Sign

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

The company cited strategic business reasons for halting the trial, though a parallel study in non-diabetic obesity patients remains ongoing.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.